Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Shares Outstanding (Diluted Average) (2022 - 2025)

Protagonist Therapeutics' Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $63.6 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 2.31% year-over-year to $63.6 million; the TTM value through Dec 2025 reached $63.6 million, down 2.31%, while the annual FY2025 figure was $63.6 million, 2.31% down from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $63.6 million at Protagonist Therapeutics, roughly flat from $63.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $65.1 million in Q4 2024 and bottomed at $44.2 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $56.8 million (2023), against an average of $55.6 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) rose 25.75% in 2024 before it dropped 2.31% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $46.3 million in 2021, then grew by 6.01% to $49.1 million in 2022, then increased by 15.59% to $56.8 million in 2023, then rose by 14.65% to $65.1 million in 2024, then dropped by 2.31% to $63.6 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Shares Outstanding (Diluted Average) are $63.6 million (Q4 2025), $63.4 million (Q3 2025), and $63.5 million (Q2 2025).